Auna (AUNA) Q2 2026 earnings review
Top-Line Momentum Overshadowed by Broad Margin Contraction
Auna delivered robust 13% YoY reported revenue growth (9% FX-neutral), driven by volume recovery in Mexico and a successful shift toward risk-sharing models in Colombia. However, this growth came at a steep cost. Adjusted EBITDA fell 6% YoY to S/227 million, and consolidated margins contracted by 3.7 percentage points. Mexico's profitability remains depressed due to service mix shifts and payroll investments, while Peru suffered from recurring billing penalties. Consequently, management walked back their profitability outlook, guiding FY26 Adjusted EBITDA growth toward the low end of their 10-14% target range, despite reaffirming the ~12% revenue midpoint.
🐂 Bull Case
The strategic pivot away from government-intervened payors is accelerating. Prospective Global Payment (PGP) risk-sharing contracts now represent 24% of segment revenue, insulating cash flows and driving 13% local currency growth.
Disciplined working capital management yielded a 181% YoY spike in Free Cash Flow to S/400M. The leverage ratio stabilized at 3.6x, keeping the medium-term <3.0x target viable.
🐻 Bear Case
Despite higher volumes, every geographic segment suffered YoY margin compression. Mexico's Adjusted EBITDA margin plummeted 6.1 points to 25.9%, proving that the new volume mix is structurally less profitable.
What was previously framed as a 'surprise' one-off in Q1 recurred in Q2. Accepted penalties related to prior years' receivables reconciliation dragged Peru's EBITDA growth to flat despite an 8% revenue increase.
⚖️ Verdict: 🔴
Bearish. The persistent margin compression across all three geographies indicates that Auna is paying a high operational cost to chase volume growth. Until Mexico's margins stabilize and Peru resolves its billing cycle penalties, the top-line beats are hollow.
Key Themes
Margin Squeeze Across the Board
Volume growth is failing to translate into operating leverage. Mexico's Adjusted EBITDA dropped 16% in local currency, crushing margins from 32.0% a year ago to 25.9%. Management cited higher pharmacy costs linked to service mix and talent investments affecting payroll. Similarly, Colombia's margins compressed 3.7 points YoY to 13.1% due to the variable costs of stabilizing newly onboarded PGP contracts and statutory wage hikes.
Colombia's PGP Strategy Shields the Top Line
Auna's aggressive restructuring of its payor mix in Colombia is a major operational win. PGP (risk-sharing) revenue jumped to 24% of the segment total (up from 14% a year ago), covering 3.1 million lives. Simultaneously, exposure to volatile intervened payors (like Nueva EPS) fell to just 12%. This pivot drove a 13% local currency revenue gain and improved sequential EBITDA margins.
Peru Billing Penalties Becoming Chronic
In Q1, management claimed revenue adjustments from payor penalties (due to billing cycle delays) were largely an unfortunate surprise. In Q2, these 'accepted penalties' struck again, nullifying the operating leverage from Peru's 8% revenue growth and causing consolidated Peru EBITDA to stagnate at S/101 million. This highlights an ongoing weakness in Auna's revenue cycle management.
High-Complexity B2B Volumes Expanding
Auna is successfully capturing complex, high-ticket procedures. Mexico saw radiotherapy and chemotherapy sessions surge 86% YoY, accompanied by out-of-pocket payment growth of 21%. In Peru, Oncosalud boosted plan memberships by 6% (adding 7,000 members via a new SEDAPAL B2B policy). While this is straining near-term pharmacy and medical talent costs, it cements market share in high-acuity care.
FX Volatility Shreds Net Income
Reported Net Income collapsed 61% YoY to S/33 million, almost entirely due to macro currency swings. The prior year included a S/68 million non-cash FX gain, whereas Q2 2026 saw lower non-cash gains as the Mexican and Colombian pesos appreciated against the Peruvian Sol. While hedging reduces cash impact, the accounting noise obscures underlying operational stability.
Deployment of AI and Robotic Automation
Auna is aggressively upgrading its clinical technology stack. In Mexico, the AI-powered Elekta EVO linear accelerator for adaptive radiotherapy goes live in September. In Peru, the company installed a Versius SP4 modular robotic system at Clínica Delgado for minimally invasive procedures. These investments enhance care quality and support price realization in the high-complexity tier.
Other KPIs
Accelerating significantly from S/251 million a year ago (+76%). The S/190 million improvement was driven by robust working capital management, favorable changes in trade payables (S/52M benefit), and S/34 million in lower tax payments. This translated directly into a 181% surge in Free Cash Flow.
Stable. The ratio improved sequentially from 3.7x in Q1 due to a higher cash balance (S/478 million) offsetting a slight S/74 million gross debt increase. Auna maintains its medium-term target of below 3.0x, but this path remains highly dependent on EBITDA margin recovery, as debt reduction alone is slow.
Stable. Increased slightly by 0.3 percentage points YoY but remains remarkably close to the sub-50% threshold. The slight uptick reflects the onboarding of new B2B accounts, which typically run higher initial MLRs before normalizing into the network.
Guidance
Stable. Reaffirmed by management, implying a midpoint of ~12% growth. The sustained expansion of the PGP contracts in Colombia and volume recovery in Mexico underpin this confidence.
Decelerating. Management explicitly walked back profitability expectations to the 'low end' of the original range, citing temporary cost pressures across all three geographies and expressly excluding the impact of the Peru billing penalties. This confirms margin compression will persist into H2.
Stable. Organic maintenance CapEx remains disciplined and unchanged, relying heavily on finance leases to fund major medical equipment acquisitions (like the new robotic systems).
Key Questions
Peru Billing Penalties Timeline
The 'accepted penalties' for prior-year billing reconciliations weighed heavily on Peru's EBITDA again. When exactly will these legacy reconciliations cycle out of the financials, and what structural changes to the revenue cycle management have been implemented to prevent future recurrences?
Mexico Margin Floor
Mexico's Adjusted EBITDA margin dropped 600 basis points YoY. Given the stated shift toward higher pharmacy costs and permanent talent investments, how much of this margin compression is a structural reset versus a temporary onboarding phase? What is the new baseline expectation?
PGP Margin Trajectory in Colombia
The pivot to PGP contracts in Colombia has successfully defended revenue and cash flow, but segment margins remain depressed. How long is the typical 'stabilization' period for a new PGP cohort before clinical pathways are optimized and margins inflect upward?